However, Nakajima et al. showed that Gal-3 cleavage in the bone tumor microenvironment (TME) of breast and prostate cancers delays osteoclastogenesis by targeting the carbohydrate recognition domain (CRD) of Gal-3 [30]. This evidence concerns the gene LGALS3 and prostate carcinoma.